In 1079 patients with atrial fibrillation having PCI, 1-month DOAC plus P2Y12 inhibitor then DOAC alone was non-inferior to 12 months for death or thromboembolism at 12 months (5.4% vs 4.3%) and halved major or clinically relevant bleeding (4.5% vs 8.8%; HR 0.50).
RCTn = 1,088
Sotomi et al. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial